scholarly journals Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features

2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Kun-Hsing Yu ◽  
Ce Zhang ◽  
Gerald J. Berry ◽  
Russ B. Altman ◽  
Christopher Ré ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Image Features ◽  
Small Cell ◽  
Cancer Prognosis ◽  
Small Cell Lung ◽  
Microscopic Pathology ◽  
Pathology Image

scholarly journals The role of lactate deshydrogenase levels on non-small cell lung cancer prognosis: a meta-analysis

2019 ◽  
Vol 65 (1) ◽  
pp. 89 ◽  
Author(s):  
Ting Gong ◽  
Jun Liu ◽  
Jun Jiang ◽  
Yi-Fan Zhai ◽  
Chun-Min Wu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Cancer Prognosis ◽  
Small Cell Lung

The role of genetic and other biomarkers in NSCLC prognosis

Open Medicine ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. 382-390
Author(s):  
Diana Schveigert ◽  
Saulius Cicenas ◽  
Jaroslav Bublevic ◽  
Renatas Askinis ◽  
Virginijus Sapoka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Strategies ◽  
Small Cell ◽  
Cancer Prognosis ◽  
Lung Carcinogenesis ◽  
Small Cell Lung ◽  
Multistep Process ◽  
New Treatment

AbstractThe development of non-small-cell lung cancer (NSCLC) is a multistep process, which is triggered and maintained by various factors. Many steps of non-small-cell lung carcinogenesis, risk factors and biomarkers have been identified; however no consistent model has been established of personalized medicine for these patients. Distinct various gene expression, products of mutated genes and other markers such as circulating nucleic acids or tumor cells has been proven to be potential biomarkers of non-small cell lung cancer as well as potential targets for new treatment strategies. This article will highlight promising biomarkers in non-small cell lung cancer prognosis.

Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis

Tumor Biology ◽  
2014 ◽  
Vol 35 (7) ◽  
pp. 7155-7162 ◽  
Author(s):  
Xinwen Zhong ◽  
Xiaojiao Guan ◽  
Qianze Dong ◽  
Shize Yang ◽  
Wenke Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Cancer Prognosis ◽  
Proliferation Marker ◽  
Small Cell Lung

scholarly journals N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non–Small Cell Lung Cancer Prognosis

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhenyu Zhao ◽  
Qidong Cai ◽  
Pengfei Zhang ◽  
Boxue He ◽  
Xiong Peng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Alternative Splicing ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Regulatory Genes ◽  
Mrna Splicing ◽  
Cancer Prognosis ◽  
Small Cell Lung ◽  
Rna Methylation

Aberrant N6-methyladenosine (m6A) RNA methylation regulatory genes and related gene alternative splicing (AS) could be used to predict the prognosis of non–small cell lung carcinoma. This study focused on 13 m6A regulatory genes (METTL3, METTL14, WTAP, KIAA1429, RBM15, ZC3H13, YTHDC1, YTHDC2, YTHDF1, YTHDF2, HNRNPC, FTO, and ALKBH5) and expression profiles in TCGA-LUAD (n = 504) and TCGA-LUSC (n = 479) datasets from the Cancer Genome Atlas database. The data were downloaded and bioinformatically and statistically analyzed, including the gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. There were 43,948 mRNA splicing events in lung adenocarcinoma (LUAD) and 46,020 in lung squamous cell carcinoma (LUSC), and the data suggested that m6A regulators could regulate mRNA splicing. Differential HNRNPC and RBM15 expression was associated with overall survival (OS) of LUAD and HNRNPC and METTL3 expression with the OS of LUSC patients. Furthermore, the non–small cell lung cancer prognosis-related AS events signature was constructed and divided patients into high- vs. low-risk groups using seven and 14 AS genes in LUAD and LUSC, respectively. The LUAD risk signature was associated with gender and T, N, and TNM stages, but the LUSC risk signature was not associated with any clinical features. In addition, the risk signature and TNM stage were independent prognostic predictors in LUAD and the risk signature and T stage were independent prognostic predictors in LUSC after the multivariate Cox regression and receiver operating characteristic analyses. In conclusion, this study revealed the AS prognostic signature in the prediction of LUAD and LUSC prognosis.

Sign in / Sign up

Export Citation Format

Share Document